Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03228537 · ClinicalTrials.gov registry record · Phase 1
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
A Phase 1 study of Epithelioid Mesothelioma and Biphasic Mesothelioma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 20
- Study locations
NCT03228537 is a Phase 1 study of Epithelioid Mesothelioma and Biphasic Mesothelioma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 28 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT03228537, a Phase 1 study of Epithelioid Mesothelioma and Biphasic Mesothelioma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy works in treating patients with stage I-III pleural malignant mesothelioma. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, pemetrexed disodium, and cisplatin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving atezolizumab after surgery may kill any remaining tumor cells.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Cisplatin
- DRUG Pemetrexed Disodium
- PROCEDURE Extrapleural Pneumonectomy
- PROCEDURE Pleurectomy
Study Locations (20)
Colorado
- Penrose-Saint Francis Healthcare - Colorado Springs
- Rocky Mountain Cancer Centers-Penrose - Colorado Springs
- AdventHealth Porter - Denver
- CommonSpirit Cancer Center Mercy - Durango
- Mercy Medical Center - Durango
- Mountain Blue Cancer Care Center - Golden
- Rocky Mountain Cancer Centers-Lakewood - Lakewood
- Saint Anthony Hospital - Lakewood
- AdventHealth Littleton - Littleton
- Longmont United Hospital - Longmont
- Rocky Mountain Cancer Centers-Longmont - Longmont
- AdventHealth Parker - Parker
- Rocky Mountain Cancer Centers-Parker - Parker
- Saint Mary Corwin Medical Center - Pueblo
California
- PCR Oncology - Arroyo Grande
- City of Hope Comprehensive Cancer Center - Duarte
- University of California Davis Comprehensive Cancer Center - Sacramento
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
Arkansas
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-07-16 |
| Est. Completion | 2026-09-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03228537
The ClinicalTrials.gov registry entry for NCT03228537 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Epithelioid Mesothelioma appearing as the primary indexed condition, and to 5 interventions - of which Atezolizumab is the first listed.
NCT03228537 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Colorado, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03228537 about?
NCT03228537 is a clinical study titled "Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma". This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy works in treating patients with stage I-III pleural malignant mesothelioma. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune...
What is the current status of trial NCT03228537?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2018-07-16. Estimated completion is 2026-09-18.
What conditions does trial NCT03228537 study?
This clinical trial studies the following conditions: Epithelioid Mesothelioma, Biphasic Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v7, Stage IA Pleural Malignant Mesothelioma AJCC v7, Stage IB Pleural Malignant Mesothelioma AJCC v7.
What interventions are being tested in trial NCT03228537?
The interventions under investigation include: Atezolizumab (DRUG), Cisplatin (DRUG), Pemetrexed Disodium (DRUG), Extrapleural Pneumonectomy (PROCEDURE), Pleurectomy (PROCEDURE).
Who is sponsoring clinical trial NCT03228537?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03228537 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epithelioid Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.